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Abstract: We report a new type of multifunctional nanomaterials, FePt@Fe2O3 yolk-shell nanoparticles,
that exhibit high cytotoxicity originated from the FePt yolks and strong MR contrast enhancement resulting
from the Fe2O3 shells. Encouraged by the recently observed high cytotoxicity of FePt@CoS2 yolk-shell
nanoparticles, we used Fe2O3 to replace CoS2 as the shells to further explore the applications of the
yolk-shell nanostructures. The ultralow IC50 value (238 ( 9 ng of Pt/mL) of FePt@Fe2O3 yolk-shell
nanoparticles likely originates from the fact that the slow oxidation and release of FePt yolks increases the
cytotoxicity. Moreover, compared with two commercial magnetic resonance imaging (MRI) contrast agents,
MION and Sinerem, the FePt@Fe2O3 yolk-shell nanoparticle showed stronger contrast enhancement
according to their apparent transverse relaxivity values (r2* ) 3.462 (µg/mL)-1 s-1). The bifunctional
FePt@Fe2O3 yolk-shell nanoparticles may serve both as an MRI contrast agent and as a potent anticancer
drug. This work indicates that these unique yolk-shell nanoparticles may ultimately lead to new designs
of multifunctional nanostructures for nanomedicine.
Introduction
In this paper we describe FePt@Fe2O3 yolk-shell nanopar-
ticles to exhibit both a magnetic resonance imaging (MRI)
contrast enhancing effect and a potent cytotoxicity toward HeLa
cells. Because of the capability of combining multiple func-
tionalities into a single entity on the nanoscale in an unprec-
edented way, nanotechnology offers the opportunity to develop
a multifunctional nanostructure for multipurpose applications;
for example, such nanostructures can not only monitor and detect
the cellular changes associated with disease pathogenesis but
also treat the disease at the cellular level. Recently, the
multidisciplinary developments in the fields of physics, chem-
istry, and biology have led to the rational design and use of
multifunctional nanomaterials for biomedical applications, such
as cell imaging, drug delivery, diagnosis, and therapeutics.1-11
Among the nanostructures being actively explored, magnetic
nanomaterials (e.g., Fe3O4 nanoparticles and γ-Fe2O3 nanopar-
ticles) are emerging as a new type of nanomedicine for the
treatment of various diseases (e.g., cancers) because they can
serve as MRI contrast agents12-19 or as magnetic-field-guided
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drug delivery vehicles.20-22 The unique properties and exciting
applications of magnetic nanomaterials have inspired the
fabrication of multifunctional nanostructures based on magnetic
nanoparticles, such as FePt-CdX (X ) S, Se) heterodimer (or
core-shell) nanoparticles,23,24 Fe3O4-Ag or Fe3O4-CdSe het-
erodimer nanoparticles,25,26 and Au-Fe3O4 dumbbell-like bi-
functional nanoparticles.27 Recently, on the basis of the
yolk-shell nanostructures reported by Alivisatos and co-
workers, we developed FePt@CoS2 yolk-shell nanoparticles
that could serve as an anticancer agent because of their ultrahigh
cytotoxicity.28 The porous shells formed through the Kirkendall
effect29-32 ensure the slow diffusion of platinum ions out of
the shells to yield exceptionally high cytotoxicity. The slow
dissolution of the uncoated FePt yolks dramatically increases
the cytotoxicity of these yolk-shell nanoparticles, which
represent a new type of controlled drug delivery system.33 This
finding encouraged us to further study the potential applications
of this type of nanostructures on the basis of the surface
chemistry of the shell and the composition of the yolk.
Herein, we designed and synthesized FePt@Fe2O3 yolk-shell
nanoparticles through the Kirkendall effect with FePt nanopar-
ticles34 serving as the seeds. Because of the cytotoxicity
originating from the FePt yolk and MRI effects due to the Fe2O3
shell, these FePt@Fe2O3 yolk-shell nanoparticles exhibit dual
functions, which may lead to a new strategy to combine
diagnostic and therapeutic agents. Compared to the conventional
treatments of magnetic nanoparticles for drug delivery, such as
polymer coatings, which may require complicated processes and
result in modest efficiency,35,36 the direct encapsulation of the
precursor of the drugs or the therapeutic agents by the growth
of an iron oxide shell could dramatically simplify the production
process. Moreover, the strategy described here may lead to a
new type of drugs that kill pathogenic cells by slow release of
active agents from the yolk-shell magnetic nanoparticles.
Results and Discussion
Fabrication and Characterization of the Multifunctional
Yolk-Shell Nanoparticles. Recently, several groups have syn-
thesized iron oxide hollow nanoparticles based on the oxidiza-
tion of iron nanoparticles by the Kirkendall effect on the
nanoscale,37-39 which encouraged us to use iron oxide as the
shell for yolk-shell nanostructures.29 Using FePt nanoparticles
(about 3 nm in diameter) as the seeds, we directly injected the
solution of Fe(CO)5 into the refluxing solution of 1-octadecene
containing oleylamine and FePt nanoparticles to form FePt@Fe
core-shell nanoparticles as the intermediate (Figure S1, Sup-
porting Information). These as-prepared FePt@Fe core-shell
nanoparticles in 1-octadecene were exposed to the ambient
atmosphere and heated to 180 °C in the presence of O2 flowing
with a rate of 2 m3/h. At the end of the 2 h oxidization,
FePt@Fe2O3 yolk-shell nanoparticles were obtained by cen-
trifugation. As shown in the transmission electron microscopy
(TEM) image (Figure 1A), the FePt@Fe2O3 yolk-shell nano-
particles have a structure similar to that of other yolk-shell
nanoparticles (e.g., FePt@CoS228 or Pt@CoO29 yolk-shell
nanoparticles) due to the Kirkendall effect occurring on the
shell of the FePt@Fe core-shell intermediates. The high-
resolution TEM (HRTEM) image of FePt@Fe2O3 yolk-shell
nanoparticles (Figure 1B) indicates that both the FePt yolk and
the Fe2O3 shell are crystalline.
To investigate the stability of FePt cores in the organic solvent
during oxidation, we carried out the oxidation experiment just
using the as-prepared FePt nanoparticles under conditions similar
to those used for oxidizing FePt@Fe nanoparticles. The TEM
images and selected area electron diffraction pattern (EDP)
analysis (Figure S2, Supporting Information) indicate that the
FePt nanoparticles still maintain a highly crystalline structure
(fcc phase) without a significant size change after oxidation.
Magnetism analysis (Figure S2, Supporting Information) shows
that the FePt nanoparticles retain superparamagnetic behavior
with little change in the blocking temperature (∼15 K) after
being treated under the oxidative condition. These results
confirm that the as-prepared FePt nanoparticles are stable enough
in the organic solvent under the oxidization conditions and can
serve as the seeds for making the yolk-shell nanoparticles.
Energy-dispersive X-ray spectroscopy (EDS) analysis (Figure
S3, Supporting Information) indicates that the core of
FePt@Fe2O3 yolk-shell nanoparticles mainly consists of Fe and
Pt and the shell only consists of Fe, suggesting that the FePt
cores remain unchanged after the oxidization process. X-ray
fluorescence (XRF) spectroscopy analysis indicates that the
molar ratio of FePt to Fe2O3 is 1:41, corresponding to ∼28.7
ng of Pt/µg of FePt@Fe2O3 yolk-shell nanoparticles (Figure
S4, Supporting Information).
To investigate the bifunctional FePt@Fe2O3 yolk-shell
nanoparticles in detail, we further made three other types of
relevant nanostructures, Pt@Fe2O3 yolk-shell nanoparticles,
FePt@Fe3O4 core-shell nanoparticles, and γ-Fe2O3 hollow
nanoparticles, as the control samples. The different yolk
compositions (e.g., Pt yolk versus FePt yolk) and the morphol-
ogies of the nanostructures (e.g., core-shell versus yolk-shell)
would certainly dictate the properties and functions of these
nanomaterials. By utilizing Pt nanoparticles as seeds, a method
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similar to the synthesis of FePt@Fe2O3 yolk-shell nanoparticles
gives Pt@Fe2O3 yolk-shell nanoparticles (Figure 1C,D).
FePt@Fe3O4 core-shell nanoparticles (Figure 1E,F) were
synthesized by the coating of FePt cores with Fe3O4 shells
through the thermal decomposition of Fe(acac)3.40 The direct
oxidization of the as-prepared iron nanoparticles by O2 can give
a product of γ-Fe2O3 hollow nanoparticles (Figure 1G,H).
Because of the harsh oxidative condition, instead of Fe3O4
nanoparticles, Fe2O3 nanoparticles become the favorable prod-
uct. EDP analysis (Figure S5, Supporting Information) indicates
that these Fe2O3 hollow nanoparticles are in the γ phase41 with
high crystallinality (Figure 1H), possibly because the oxidation
also occurs at a relatively high temperature.
Magnetic Properties. The magnetic measurement, performed
immediately after the synthesis of the nanoparticles, reveals the
superparamagnetism of these nanostructures. Standard zero-
field-cooling (ZFC) and field-cooling (FC) measurements give
estimated blocking temperatures of about 36 K for the FePt@
Fe2O3 yolk-shell nanoparticles and 46 K for the Pt@Fe2O3
yolk-shell nanoparticles, respectively (Figure 2A,B), suggesting
(40) Zeng, H.; Li, J.; Wang, Z. L.; Liu, J. P.; Sun, S. H. Nano Lett. 2004,
4, 187.
(41) Shevchenko, E. V.; Kortright, J. B.; Talapin, D. V.; Aloni, S.;
Alivisatos, A. P. AdV. Mater. 2007, 19, 4183.
Figure 1. TEM (A, C, E, and G) and HRTEM (B, D, F, and H) images of FePt@Fe2O3 yolk-shell nanoparticles (A, B), Pt@Fe2O3 yolk-shell nanoparticles
(C, D), and FePt@Fe3O4 core-shell nanoparticles (E, F) obtained by the seed-growth method and γ-Fe2O3 hollow nanoparticles (G, H) synthesized via the
Kirkendall effect.
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that they exhibit superparamagnetic behaviors at room temper-
ature. The overall size of the FePt@ Fe2O3 yolk-shell nano-
particles (∼8 nm in diameter) is smaller than that of the
Pt@Fe2O3 yolk-shell nanoparticles (∼10 nm in diameter),
resulting in a slightly lower blocking temperature of the
FePt@Fe2O3 yolk-shell nanoparticles. The well-defined sharp
peaks indicate these two kinds of nanoparticle samples having
narrow size distributions. SQUID magnetometry (ZFC/FC)
measurements of FePt@Fe3O4 core-shell nanoparticles give a
blocking temperature of about 110 K with a broad peak (Figure
2C), suggesting that there are strong magnetic dipole-dipole
and/or exchange interactions among the particles, in addition
to the exchange coupling between FePt cores and Fe3O4 shells
within the particles that agrees with the core-shell nanostruc-
tures. The blocking temperature of γ-Fe2O3 hollow nanoparticles
is about 50 K with a well-defined sharp peak (Figure 2D), due
to the large size (∼12 nm in diameter) and the excellent
crystallinality of the nanoparticles.
The field-dependent magnetization measurements show that
all four of these nanoparticles are superparamagnetic and lack
any hysteresis loops at room temperature (Figure 3). The
saturated magnetization (Ms) of γ-Fe2O3 hollow nanoparticles
is about 50.8 emu/g, the highest value among those four samples,
further confirming the high crystallinality of the γ-Fe2O3 hollow
nanoparticles. The Ms values are 25.2, 19.5, and 24.8 emu/g
for FePt@Fe2O3 yolk-shell, Pt@Fe2O3 yolk-shell, and
FePt@Fe3O4 core-shell nanoparticles, respectively.
Investigation of MR Contrast Enhancement. After the simple
surface modification of the nanoparticles by 3,4-dihydroxy-L-
phenylalanine (L-dopa) molecules, these four types of nanopar-
ticles(FePt@Fe2O3yolk-shellnanoparticles,Pt@Fe2O3yolk-shell
nanoparticles, FePt@Fe3O4 core-shell nanoparticles, and
γ-Fe2O3 hollow nanoparticles) dispersed very well in water
(Figure S6, Supporting Information) because L-dopa or its
analogues (e.g., dopamine) can serve as stable, hydrophilic
surface modifiers for iron oxide nanoparticles.42 To compare
the MR apparent transverse relaxivities (r2*) of these magnetic
nanoparticles, we acquired multiecho gradient echo images (TR
(repetition time) ) 2 s with TEs (echo times) of 3, 6, 9, 12, 15,
18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48 ms and a flip
angle of 30°) for each sample with a 7 T MRI scanner with a
maximum gradient of 360 mT/m. As shown in Figure 4, γ-Fe2O3
hollow nanoparticles exhibit the strongest MR signal attenuation
effect among five types of particles (the above-mentioned four
(42) Gao, J. H.; Xu, B. Unpublished results.
Figure 2. Temperature dependence of the ZFC/FC magnetization (at a magnetic field of 100 Oe) of (A) FePt@Fe2O3 yolk-shell nanoparticles, (B) Pt@Fe2O3
yolk-shell nanoparticles, (C) FePt@Fe3O4 core-shell nanoparticles, and (D) γ-Fe2O3 hollow nanoparticles in hexane solution.
Figure 3. Room-temperature field-dependent magnetization measurements
of FePt@Fe2O3 yolk-shell nanoparticles (red circles), Pt@Fe2O3 yolk-shell
nanoparticles (green circles), FePt@Fe3O4 core-shell nanoparticles (white
circles), and γ-Fe2O3 hollow nanoparticles (blue circles).
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samples and cysteine-coated FePt nanoparticles, FePt@Cys
nanoparticles28). FePt@Fe2O3 yolk-shell nanocrystals and
Pt@Fe2O3 yolk-shell nanoparticles also showed strong MR
relaxation enhancement. However, FePt@Fe3O4 core-shell
nanoparticles and FePt@Cys nanoparticles (∼3 nm in diameter)
exhibit a very weak MR contrast enhancement effect. The
control of magnetic spins by changing the structure of the
nanoparticles might be critical for modulating the spin-spin
relaxation processes of protons in the water molecules sur-
rounding the nanoparticles,43 especially for hollow or solid
nanoparticles. We used relaxivity values (r2*) to quantitatively
evaluate the MR contrast enhancement for these five samples
(Table 1). The r2* values are 3.462, 1.581, 1.053, 10.466, and
0.179 (µg/mL)-1 s-1, respectively, for FePt@Fe2O3 yolk-shell,
Pt@Fe2O3 yolk-shell, FePt@Fe3O4 core-shell, γ-Fe2O3 hol-
low, and FePt@Cys nanoparticles. Compared with two com-
mercial contrast agents, MION (r2* ) 2.778 (µg/mL)-1 s-1)
and Sinerem (r2* ) 2.450 (µg/mL)-1 s-1),44,45 along with
γ-Fe2O3 hollow nanoparticles, FePt@Fe2O3 yolk-shell nano-
particles also show much stronger MR contrast enhancement,
suggesting that FePt@Fe2O3 yolk-shell nanoparticles poten-
tially can serve as a novel, efficient MR contrast agent. It is
noteworthy that this is the first report of the MRI of hollow
magnetic nanoparticles suggesting that hollow magnetic nano-
particles may exhibit advantages in MR relaxation enhancement
due to their unique geometry. The interface between the iron
oxide hollow nanoparticles and water phase is much larger than
that of solid nanoparticles under the same concentrations, which
may contribute to the stronger MR contrast enhancement per
unit weight.
Cell Assay. We used these water-dispersible nanoparticles to
treat HeLa cells for 3 days over the same range of dosages for
evaluating their cytotoxicities. According to the 3-(4,5-dimeth-
ylthiazol-2-y1)-2,5-diphenyltetrazolium bromide (MTT) assay
results (Figure 5), FePt@Fe2O3 yolk-shell nanoparticles have
the highest cytotoxicity among these four types of nanoparticles.
Likely due to the same possible mechanism of cytotoxicity of
FePt@CoS2 yolk-shell nanoparticles,28 FePt@Fe2O3 yolk-shell
nanoparticles showed an ultralow IC50 value in terms of Pt (238
( 9 ng of Pt/mL), which is similar to that of cisplatin (230 ng
of Pt/mL).46 According to the mechanism, the platinum ions,
resulting from the oxidization and disruption of the “naked”
FePt yolks (Figure S8, Supporting Information), likely bind with
DNA double helix structures, interrupt the replication and
transcription process, and lead to apoptosis of the HeLa cells.
The Pt nanocrystals in Pt@Fe2O3 yolk-shell nanoparticles
are stable because of the relative inertness of the Pt yolk.
The FePt nanoparticles in FePt@Fe3O4 core-shell nanopar-
ticles are very stable because the biocompatible, compact
Fe3O4 shells prevent the oxidative species from reaching the
FePt core.28 Therefore, there are two essential requirements
for this kind of nanostructures to serve as an effective drug
to kill cancer cells. One is the relatively reactive platinum-
containing yolks to ensure redox reaction under proper
conditions to form platinum ions; the other is good perme-
ability of the shells or disruption of the shells to allow the
metal ions to diffuse out of or be released from the shells.
This result suggests that yolk-shell nanoparticles may evolve
to become useful and effective drugs for the treatment of
cancer.
Conclusion
Compared with the FePt@CoS2 yolk-shell nanoparticles we
have reported recently, FePt@Fe2O3 yolk-shell nanoparticles
offer several distinct advantages. First, the biocompatibility of
Fe2O3 nanoshells ensures the origin of cytotoxicity from the
naked FePt yolk and minimizes the possible sources for
unwanted side effects caused by the shell. Second, the Fe2O3
nanoshells allow tumor-targeted molecules (e.g., antibodies of
specific cancer cells) to be anchored on the shell surface fairly
(43) Koenig, S. H.; Kellar, K. E. Magn. Reson. Med. 1995, 34, 227.
(44) Wu, E. X.; Wong, K. K.; Andrassy, M.; Tang, H. Y. Magn. Reson.
Med. 2003, 49, 765.
(45) Wu, E. X.; Tang, H. Y.; Jensen, J. H. NMR Biomed. 2004, 17, 478.
(46) Giovagnini, L.; Ronconi, L.; Aldinucci, D.; Lorenzon, D.; Sitran, S.;
Fregona, D. J. Med. Chem. 2005, 48, 1588.
(47) Xu, C. J.; Xu, K. M.; Gu, H. W.; Zheng, R. K.; Liu, H.; Zhang, X. X.;
Guo, Z. H.; Xu, B. J. Am. Chem. Soc. 2004, 126, 9938.
(48) Fan, X. W.; Lin, L. J.; Dalsin, J. L.; Messersmith, P. B. J. Am. Chem.
Soc. 2005, 127, 15843.
(49) Wang, L.; Yang, Z. M.; Gao, J. H.; Xu, K. M.; Gu, H. W.; Zhang, B.;
Zhang, X. X.; Xu, B. J. Am. Chem. Soc. 2006, 128, 13358.
Figure 4. T2*-weighted MR images of (A) FePt@Fe2O3 yolk-shell
nanoparticles, (B) Pt@Fe2O3 yolk-shell nanoparticles, (C) FePt@Fe3O4
core-shell nanoparticles, (D) γ-Fe2O3 hollow nanoparticles, and (E) FePt
nanoparticles from a 7.0 T MRI system at 25, 50, and 100 µg/mL in water
(containing 1% agarose gel).
Table 1. Relaxation Rate (R2*) and Relaxivity (r2*) Values of the
Samples
sample R2* at 40 µg/mL (s-1) r2* [(µg/mL)-1s-1]
FePt@Fe2O3 yolk-shell 125.2 3.462
Pt@Fe2O3 yolk-shell 72.1 1.581
FePt@Fe3O4 core-shell 50.0 1.053
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easily by using dopamine and its derivatives as reliable anchors
to immobilize functional molecules onto the yolk-shell
nanoparticles,47-51 which would help reduce the side effects.
Third, MR relaxation enhancement effects of Fe2O3 nanoshells
may provide a direct means for measuring the prognosis during
the cancer treatments. Although the long-time stability of
Fe2O3 nanoshells in vivo remains to be examined in detail,
the bifunctional FePt@Fe2O3 yolk-shell nanoparticles sug-
gest that this type of nanostructures may lead to novel
nanomedicines that perform both diagnostic and therapeutic
functions. Given the capability of surface functionalization of
these multifunctional nanoparticles by disease-specific molecules
(e.g., antibodies), one can develop yolk-shell nanoparticles that
target a specific tissue or cell type for delivering therapeutic
agents to tumors and detecting and monitoring the transforma-
tion of the tumor by noninvasive MR imaging. Moreover, the
investigation of such multifunctional nanostructures may lead
to the development of other types of multifunctional magnetic
nanomaterials as novel therapeutics.
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Figure 5. Results of the MTT assay of HeLa cells treated by (A) FePt@Fe2O3 yolk-shell nanocrystals, (B) Pt@Fe2O3 yolk-shell nanoparticles, (C)
FePt@Fe3O4 core-shell nanoparticles, and (D) γ-Fe2O3 hollow nanoparticles at 10, 20, and 40 µg/mL for 3 days.
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